Narrowband UVB Phototherapy vs Topical Calcineurin Inhibitors

Narrowband UVB can treat broader areas through supervised light exposure, while topical calcineurin inhibitors target selected patches without ultraviolet exposure.

The main distinction is where treatment acts. Narrowband UVB exposes planned skin areas to a measured light dose in a clinic. A topical calcineurin inhibitor is applied to the affected skin and works locally on inflammatory immune signals. One approach involves appointments and protective equipment; the other depends on correct application and regular skin care.

A dermatologist may consider narrowband UVB when inflammation or pigment change affects a larger or difficult-to-manage surface, or when a topical product would be impractical to spread consistently. It may also be discussed when a person prefers a supervised course with dose changes based on the skin response. Attendance, transport and protection of unaffected skin are part of the decision.

A topical calcineurin inhibitor may suit a limited area, sensitive site or treatment plan where repeated steroid use is a concern. It is applied thinly to diagnosed affected skin and is often paired with moisturising and trigger avoidance. Early warmth, stinging or itching can occur; these sensations should be discussed if they persist or make application difficult.

Narrowband UVB can cause dryness, redness or an exposure reaction, and the clinic must know about medicines that increase light sensitivity. Topical calcineurin inhibitors can cause temporary burning or warmth at the application site and should not be used on an untreated infection. Neither option replaces confirmation of the diagnosis. Stop and seek clinical advice for worsening pain, spreading redness, blisters or eye involvement.

Neither option may be enough when the condition is severe, rapidly spreading, infected or not responding to the working diagnosis. A very small isolated patch may need a different local medicine, while extensive disease may need a broader treatment plan. If the skin changes after starting treatment, reassessment can be more useful than simply increasing application or light exposure.

The clinician weighs diagnosis, body site, surface area, skin sensitivity and previous treatment response. They ask whether you can attend regular light sessions or apply medicine consistently, then review other medicines and infection risk. For topical treatment, technique and quantity matter; for phototherapy, dose escalation, eye protection and shielding matter. The recommendation should include a review point and a clear action for troublesome reactions.